

# Eric S Leifer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/903891/publications.pdf>

Version: 2024-02-01

13  
papers

2,465  
citations

932766

10  
h-index

1199166

12  
g-index

13  
all docs

13  
docs citations

13  
times ranked

3158  
citing authors

#	ARTICLE	IF	CITATIONS
1	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 109.e1-109.e8.	0.6	12
2	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 227.	3.8	89
3	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. <i>Blood</i> , 2021, 137, 420-428.	0.6	119
4	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	13.9	778
5	Joint testing of overall and simple effects for the two-by-two factorial trial design. <i>Clinical Trials</i> , 2021, 18, 521-528.	0.7	5
6	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	13.9	712
7	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1703.	3.8	186
8	The influence of comorbidities on achieving an N-terminal pro-B-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. <i>ESC Heart Failure</i> , 2021, , .	1.4	3
9	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. <i>JAMA Cardiology</i> , 2020, 5, 757.	3.0	74
10	Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. <i>European Journal of Heart Failure</i> , 2019, 21, 770-778.	2.9	36
11	Discussion of a Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III by Andrew G. Chapple and Peter F. Thall. <i>Biometrics</i> , 2019, 75, 382-384.	0.8	0
12	NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2019, 7, 158-168.	1.9	65
13	Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 713.	3.8	386